Clinical Trials Logo

Filter by:
NCT ID: NCT06288893 Not yet recruiting - COVID-19 Clinical Trials

SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19)

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

Randomized, double-blind, placebo-controlled, multicenter phase II clinical study of SHEN211 tablets

NCT ID: NCT06288841 Recruiting - Clinical trials for Pharmacological Action

Efficacy and Safety of Liposomal Bupivacaine Under ERAS Concept for Postoperative Analgesia of Ultrasound-Guided QLB in Gynecologic Laparoscopic Patients: A Randomized, Single-blind, Active-Controlled Clinical Study

Start date: November 30, 2023
Phase: N/A
Study type: Interventional

With the development of the concept of comfortable medicine and enhanced recovery surgery (ERAS), optimizing the perioperative management of patients, reducing surgical stress, and reducing postoperative pain can effectively reduce perioperative complications and achieve the purpose of accelerating recovery. As an important part of ERAS, multimodal analgesia is the core concept of perioperative analgesia management. As a kind of perioperative multimodal analgesia, quadratus lumbar muscle block (QLB) is a type of local anesthetic drug injected around the quadratus lumbar muscle to reduce or eliminate abdominal wall pain and visceral pain after abdominal surgery. QLB has been used successfully for pain control after laparoscopic and open surgery, reducing perioperative opioid use and improving prognosis-related measures such as PONV and length of hospital stay. Bupivacaine liposomes use DepoFoam technology to encapsulate the drug in polycystic liposomes, which can prolong the release time of bupivacaine due to the different rupture times of different vesicles, and the postoperative analgesia can be up to 72 hours. In this project, patients who undergo elective laparoscopic uterine and double adnexectomy were selected to be injected with lipososomes of bupivacaine at different concentrations under ultrasound guidance of bilateral posterior QLB before anesthesia induction, and the effect of liposomal bupivacaine on postoperative pain was investigated by evaluating the postoperative pain and incidence of adverse events. This study will greatly promote the clinical promotion and application of bupivacaine liposome, improve the postoperative comfort and satisfaction of patients, and accelerate the postoperative recovery of patients.

NCT ID: NCT06288750 Recruiting - Indocyanine Green Clinical Trials

Protective Effect of Indocyanine Green Fluorescence Imaging Technology on Parathyroid Glands During Total Thyroidectomy

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

Accurate identification and evaluation of the parathyroid glands (PGs) intraoperatively is critical to reduce the incidence of postoperative hypoparathyroidism after total thyroidectomy. Near-infrared fluorescence imaging (NIFI), including the autofluorescence (AF) and indocyanine green fluorescence (ICGF) imaging, is a promising technique to protect PGs. This study aimed to assess whether the combined use of AF and ICGF could reduce the incidence of postoperative hypoparathyroidism and improve the identification and evaluation of PGs during total thyroidectomy.

NCT ID: NCT06288659 Recruiting - Clinical trials for Aneurysmal Subarachnoid Hemorrhage

aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial

ASTIM-MT
Start date: May 20, 2024
Phase: N/A
Study type: Interventional

ASTIM is a multicenter, prospective, randomised, blinded end-point assessed trial, to investigate the efficacy and safety of treatment based on intracranial pressure monitoring in improving the prognosis of patients with aneurysmal subarachnoid hemorrhage.

NCT ID: NCT06288620 Recruiting - Breast Cancer Clinical Trials

Microwave Ablation in the Treatment of Early-stage Unifocal Invasive Breast Cancer

Start date: February 25, 2024
Phase: N/A
Study type: Interventional

Microwave Ablative (MWA) therapy, as a minimally invasive thermal therapy, has been attempted to treat breast cancer of small lesions . However, the optimal indications for MWA in the treatment of breast cancer is unknown. This prospective, open-label, single-arm phase II clinical study was conducted to evaluate the efficacy and safety of MWA in the treatment of early-stage unifocal invasive breast cancer, and to explore the immune activating effect.

NCT ID: NCT06288607 Active, not recruiting - Solar Lentigo Clinical Trials

Safety and Efficacy of High Intensity Focused Ultrasound in Solar Lentigo: A Self-controlled Study

Start date: November 16, 2023
Phase:
Study type: Observational

This trial is a single-center, prospective self-controlled study. The study proposes to recruit 30 patients with solar lentigo on both sides of the face. Patients are randomly assigned to be treated with high-intensity focused ultrasound (MFUS One, Hunan Peninsula Medical Technology Co., Ltd., China) on one side, and the other side is not treated. The Lab* values of the lesion area and the area around the lesion are detected separately using 3nh HIGH-QUALITY COLORMETER colorimeter (Konica-Minolta Company, Japan), and skin lesion images are collected with dermatoscope and VISIA® (Canfield Company, USA). Measurements of Lab* values and related images at the same location, along with adverse events, physician and subjective global aesthetic improvement scale scores are recorded before and at week2, week 4, week6. At the end of the follow-up on the treatment side, the same parameter treatment is provided for the untreated side, and the corresponding observation items are recorded for the patient before treatment, and at week2, week4, and week6 respectively.

NCT ID: NCT06288373 Not yet recruiting - Cervical Cancer Clinical Trials

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Start date: March 1, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

It is a prospective, open-label, randomized, controlled phase II/III clinical trial in which patients with PD-L1-positive FIGO stage IB3, IIA2 and IIB(tumors >4 cm in diameter)will be enrolled and randomly divided into the neoadjuvant chemoimmunotherapy plus surgery group and the CCRT group.

NCT ID: NCT06288360 Not yet recruiting - Cervical Cancer Clinical Trials

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer.

NCT ID: NCT06288334 Recruiting - Children Clinical Trials

Exploration of the Optimal Dosage of Cetirizine in the Treatment of Allergic Diseases in Chinese Children

Start date: August 6, 2020
Phase: Phase 4
Study type: Interventional

To obtain the pharmacokinetics of cetirizine in Chinese children with allergic disease.

NCT ID: NCT06288074 Recruiting - Clinical trials for Severe Community-acquired Pneumonia

Diagnosis and Treatment Strategy Optimization of Severe Pneumonia Based on Multi-omics Data Integration

Start date: March 10, 2024
Phase:
Study type: Observational

Severe community-acquired pneumonia still has a high incidence and mortality, but the molecular mechanism and prognostic biomarkers of severe community-acquired pneumonia caused by different pathogens are still unclear, and the best treatment strategy has not been determined. Based on this, this project intends to take patients with severe community-acquired pneumonia caused by different pathogens as the research object, explore the molecular mechanism of severe community-acquired pneumonia from multiple angles, integrate relevant research data to evaluate the rationality of initial empirical medication, and lay the foundation for precise treatment of severe pneumonia. The research results will help to develop a new rapid and accurate target for clinical diagnosis and efficacy evaluation of severe pneumonia, and build a precise treatment system for severe pneumonia.